Nissay Asset Management Corp Japan ADV Sells 87 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Nissay Asset Management Corp Japan ADV decreased its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 3.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 2,394 shares of the medical research company’s stock after selling 87 shares during the quarter. Nissay Asset Management Corp Japan ADV’s holdings in Bio-Rad Laboratories were worth $792,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Nomura Holdings Inc. bought a new stake in Bio-Rad Laboratories during the 4th quarter worth about $1,004,000. Nuveen Asset Management LLC raised its position in shares of Bio-Rad Laboratories by 0.8% in the 4th quarter. Nuveen Asset Management LLC now owns 39,505 shares of the medical research company’s stock valued at $12,978,000 after acquiring an additional 327 shares during the period. OMERS ADMINISTRATION Corp grew its position in shares of Bio-Rad Laboratories by 18.4% in the 4th quarter. OMERS ADMINISTRATION Corp now owns 890 shares of the medical research company’s stock valued at $292,000 after purchasing an additional 138 shares during the period. Gotham Asset Management LLC raised its holdings in Bio-Rad Laboratories by 21.0% during the 4th quarter. Gotham Asset Management LLC now owns 21,949 shares of the medical research company’s stock worth $7,210,000 after buying an additional 3,805 shares during the period. Finally, Ethic Inc. raised its holdings in Bio-Rad Laboratories by 48.5% during the 4th quarter. Ethic Inc. now owns 1,598 shares of the medical research company’s stock worth $525,000 after buying an additional 522 shares during the period. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Up 2.2%

Shares of Bio-Rad Laboratories stock opened at $248.45 on Monday. The firm has a 50-day moving average of $243.46 and a 200-day moving average of $298.10. The stock has a market cap of $6.96 billion, a PE ratio of -3.82 and a beta of 1.00. Bio-Rad Laboratories, Inc. has a 52-week low of $215.38 and a 52-week high of $387.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Thursday, May 1st. The medical research company reported $2.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.73 by $0.81. The company had revenue of $585.40 million during the quarter, compared to analysts’ expectations of $573.01 million. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Bio-Rad Laboratories’s quarterly revenue was down 4.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.30 earnings per share. As a group, sell-side analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on BIO. StockNews.com downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Citigroup reduced their price objective on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Wells Fargo & Company reduced their price objective on shares of Bio-Rad Laboratories from $320.00 to $270.00 and set an “equal weight” rating for the company in a research report on Thursday, April 17th. UBS Group reduced their price objective on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Finally, Royal Bank of Canada reduced their price objective on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an “outperform” rating for the company in a research report on Friday, May 2nd. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $327.40.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.